QNRX surges 48.9% as EPS revision signal precedes price breakout; HELP, ACMR also climb
Today's top EPS revision plays were led by QNRX (+48.9%) and HELP (+41.5%), both healthcare names. QNRX jumped after analysts raised its forward EPS growth estimate by nearly 10 percentage points, while HELP's rally was reinforced by strong Phase 3 trial updates and a $50M offering. Technology stocks ACMR (+24.9%) and NTSK (+22.2%) also gained following upward estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| QNRX | Healthcare | 2026-06-23 | +9.5pp | +48.9% |
| HELP | Healthcare | 2026-06-21 | N/A | +41.5% |
| ACMR | Technology | 2026-06-24 | +2.2pp | +24.9% |
| CADL | Healthcare | 2026-06-21 | +9.3pp | +23.9% |
| NTSK | Technology | 2026-06-22 | N/A | +22.2% |
Why did QNRX stock jump in June 2026?
QNRX jumped 48.9% (from $3.25 to $4.84) after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23.
The surge occurred without any earnings-related news, indicating the revision itself drove investor conviction. The 9.5 percentage point upward revision in a small-cap healthcare stock likely signaled improving profitability expectations, triggering algorithmic and momentum buying.
QNRX EPS revision history → · Screener snapshot from 2026-06-23 →
FAQ: QNRX
Why did QNRX stock jump in June 2026?
QNRX jumped 48.9% after analysts raised its forward EPS growth estimate from 45.4% to 54.8% on June 23, with no additional news catalysts.
What is QNRX's EPS growth estimate?
As of the revision, QNRX's forward EPS growth estimate is 54.8%, up from 45.4%.
Is QNRX a buy after the rally?
The 48.9% surge reflects strong market conviction in the revised earnings outlook, but investors should assess valuation at $4.84 relative to fundamentals.
Why did HELP stock jump in June 2026?
HELP jumped 41.5% (from $4.67 to $6.61) after analysts raised its forward EPS growth estimate to 27.7% on June 21.
The rally accelerated after Helus Pharma reported business highlights and fiscal 2026 results on June 29, including Phase 3 enrollment progress for HLP003 in MDD and a $50 million underwritten offering. The combination of an upward EPS revision and positive clinical catalysts drove strong investor demand.
HELP EPS revision history → · Screener snapshot from 2026-06-21 →
FAQ: HELP
Why did HELP stock jump?
HELP surged 41.5% after its forward EPS growth estimate was raised to 27.7% on June 21, followed by favorable Phase 3 and financial updates on June 29.
What caused HELP's surge?
The EPS revision was the initial catalyst; later, positive Phase 3 data for HLP003 and a $50M offering reinforced the move.
Is HELP a buy after the rally?
The clinical milestones and strengthened balance sheet support the revised outlook, but the 41.5% gain may price in near-term success.
Why did ACMR stock jump in June 2026?
ACMR jumped 24.9% (from $101.60 to $126.89) after analysts raised its forward EPS growth estimate from 40.2% to 42.4% on June 24.
The modest 2.2 percentage point revision occurred in the context of strong semiconductor equipment demand, with ACMR benefiting from increased China-based spending. No company-specific news was reported in the window, suggesting the revision itself and broader sector tailwinds drove the move.
ACMR EPS revision history → · Screener snapshot from 2026-06-24 →
FAQ: ACMR
Why did ACMR stock jump in June 2026?
ACMR gained 24.9% after its forward EPS growth estimate was raised from 40.2% to 42.4% on June 24, supported by semiconductor sector momentum.
What is ACMR's EPS growth estimate?
ACMR's forward EPS growth estimate now stands at 42.4%, up from 40.2%.
What caused ACMR's surge?
The upward EPS revision combined with robust demand in the semiconductor equipment sector propelled the stock.
Why did CADL stock jump in June 2026?
CADL jumped 23.9% (from $8.31 to $10.30) after analysts raised its forward EPS growth estimate from 28.9% to 38.1% on June 21.
The 9.3 percentage point revision was one of the largest among today's screeners, reflecting a significant improvement in profitability expectations. No earnings news accompanied the move, implying the revision itself attracted buyers in the biotech space.
CADL EPS revision history → · Screener snapshot from 2026-06-21 →
FAQ: CADL
Why did CADL stock jump?
CADL rose 23.9% after analysts raised its forward EPS growth estimate from 28.9% to 38.1% on June 21, with no other news.
What is CADL's EPS growth estimate?
CADL's forward EPS growth estimate is now 38.1%, up from 28.9%.
Is CADL a buy after the rally?
The large revision suggests improved fundamentals, but the stock's jump already reflects that; watch for upcoming catalysts.
Why did NTSK stock jump in June 2026?
NTSK jumped 22.2% (from $8.95 to $10.94) after analysts raised its forward EPS growth estimate to 112.0% on June 22.
The triple-digit EPS growth estimate reflects a strong inflection in profitability for this cybersecurity firm. Without company news, the revision likely signaled accelerating earnings power, attracting growth investors in the technology sector.
NTSK EPS revision history → · Screener snapshot from 2026-06-22 →
FAQ: NTSK
Why did NTSK stock jump?
NTSK surged 22.2% after its forward EPS growth estimate was raised to 112.0% on June 22, driven by an expected profitability inflection.
What is NTSK's EPS growth estimate?
NTSK's forward EPS growth estimate is 112.0%, indicating earnings are expected to more than double.
What caused NTSK's surge?
The massive upward revision in EPS growth estimate, without any news, signaled strong future earnings potential.
Today's EPS revision plays highlight the market's appetite for earnings momentum, particularly in healthcare and technology. The strongest price reactions came from stocks with the largest revision magnitudes, confirming that estimate upgrades remain a powerful catalyst.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →